Table 1. Baseline patient characteristics.

	Arm A: gemcitabine (n=31)		Arm B: gemcitabine+200 mg WX-671 (n=31)		Arm C: gemcitabine+400 mg WX-671 (n=33)
Patient characteristics	No.	%	No.	%	No.	%
Gender
Male	14	45.2	20	64.5	12	36.4
Female	17	54.8	11	35.5	21	63.6
Age, years
Median	59		67		62
Range	48–77		48–81		39–82
ECOG performance status
0	5	16.1	4	12.9	8	24.0
1	26	83.9	27	87.1	25	76.0
Tumour localisationa
Head	25	80.6	28	90.3	30	90.9
Body	5	16.1	4	12.9	5	15.2
Tail	0	0.0	0	0.0	0	0.0
Periampullary	1	3.2	0	0.0	0	0.0
T staging
T1	0	0.0	0	0.0	1	3.0
T2	0	0.0	1	3.2	1	3.0
T3	11	35.5	15	48.4	14	42.5
T4	18	58.1	15	48.4	17	51.5
TX	2	6.5	0	0.0	0	0.0

^aMore than one localisation possible.